Avidity Biosciences, Inc. (RNA)
- PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,500 shares of its common stock and 18,750 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosci
- GuruFocus.com
Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares
President and CEO Sarah Boyce of Avidity Biosciences Inc (NASDAQ:RNA) sold 28,000 shares of the company on April 2, 2024, according to a recent SEC filing.
- PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:
